
120
90
60
30
0
Cell count
-10^3
0
10^3
10^4
10^5
Fluorescence intensity

Fig. 1A


120
90
60
30
0
Cell count
0
10^3
10^4
10^5
Fluorescence intensity

Fig. 1B


300
200
100
0
Cell count
0
10^3
10^4
Fluorescence intensity

Fig. 1C


120
90
60
30
0
Cell count
0
10^2
10^3
10^4
10^5
Fluorescence intensity

Fig. 2A


Cell count
120
90
60
30
0
0
10^2
10^3
10^4
10^5
Fluorescence intensity

Fig. 2B


Trispecific antibody 1
Trispecific antibody 2
Anti-BCMA antibody heavy chain variable region
Anti-BCMA antibody light chain variable region
Anti-CD3 antibody heavy chain variable region
Anti-CD3 antibody light chain variable region
Anti-GPRC5D nanobody
Anti-BCMA full-length antibody Fab fragment
Anti-CD3 scFv single chain antibody
Fc domain with "knob" and "hole" structure

Fig. 3


1500
1000
500
0
Fluorescence intensity
-4
-2
0
2
Log[antibody concentration]/nM
Teclistamab analogue (BCMA/CD3)
Trispecific antibody 1
Trispecific antibody 2
hIgG1 LALA isotype

Fig. 4A


400
300
200
100
0
Fluorescence intensity
-4
-2
0
2
Log[antibody concentration]/nM
Teclistamab analogue (BCMA/CD3)
Trispecific antibody 1
Trispecific antibody 2
hIgG1 LALA isotype

Fig. 4B


25000
20000
15000
10000
5000
0
Fluorescence intensity
-4
-2
0
2
Log[antibody concentration]/nM
Teclistamab analogue (BCMA/CD3)
Trispecific antibody 1
Trispecific antibody 2
hIgG1 LALA isotype

Fig. 4C


3000
2000
1000
0
Fluorescence intensity
-4
-2
0
2
Log[antibody concentration]/nM
Teclistamab analogue (BCMA/CD3)
Trispecific antibody 1
Trispecific antibody 2
hIgG1 LALA isotype

Fig. 4D


1500
1000
500
0
-4
-2
0
2
Fluorescence intensity
Log[antibody concentration]/nM
Trispecific antibody 1
BGCB491
TS-F2-5
hIgG1 LALA isotype

Fig. 4E


1000
500
0
-4
-2
0
2
Fluorescence intensity
Log[antibody concentration]/nM
Trispecific antibody 1
BGCB491
TS-F2-5
hIgG1 LALA isotype

Fig. 4F


30000
20000
10000
0
-4
-2
0
2
Fluorescence intensity
Log[antibody concentration]/nM
Trispecific antibody 1
BGCB491
TS-F2-5
hIgG1 LALA isotype

Fig. 4G


4000
3000
2000
1000
0
-4
-2
0
2
Fluorescence intensity
Log[antibody concentration]/nM
Trispecific antibody 1
BGCB491
TS-F2-5
hIgG1 LALA isotype

Fig. 4H


1500
1000
500
0
Fluorescence intensity
-4
-2
0
2
Log[antibody concentration]/nM
Teclistamab analogue (BCMA/CD3)
Trispecific antibody 1
Trispecific antibody 2
hIgG1 LALA isotype

Fig. 5A


800
600
400
200
0
Fluorescence intensity
-4
-2
0
2
Log[antibody concentration]/nM
Teclistamab analogue (BCMA/CD3)
Trispecific antibody 1
Trispecific antibody 2
hIgG1 LALA isotype

Fig. 5B


15000
10000
5000
0
Fluorescence intensity
-4
-2
0
2
Log[antibody concentration]/nM
Trispecific antibody 1
BGCB491
TS-F2-5
hIgG1 LALA isotype

Fig. 5C


15000
10000
5000
0
Fluorescence intensity
-4
-2
0
2
Log[antibody concentration]/nM
Teclistamab analogue (BCMA/CD3)
Trispecific antibody 1
Trispecific antibody 2
hIgG1 LALA isotype

Fig. 6A


Fluorescence intensity
10000
8000
6000
4000
2000
0
-4
-2
0
2
Log[antibody concentration]/nM
Teclistamab analogue (BCMA/CD3)
Trispecific antibody 1
Trispecific antibody 2
hIgG1 LALA isotype

Fig. 6B


Fluorescence intensity
2500
2000
1500
1000
500
0
-4
-2
0
2
Log[antibody concentration]/nM
Teclistamab analogue (BCMA/CD3)
Trispecific antibody 1
Trispecific antibody 2
hIgG1 LALA isotype

Fig. 7


Trispecific antibody 1
BGCB491
TS-F2-5
hIgG1 LALA isotype
Cell killing (%)
60
40
20
0
-20
-10
-8
-6
-4
-2
0
2
Log[antibody concentration]/nM

Fig. 8A


Trispecific antibody 1
BGCB491
TS-F2-5
hIgG1 LALA isotype
Cell killing (%)
60
40
20
0
-20
-10
-8
-6
-4
-2
0
2
Log[antibody concentration]/nM

Fig. 8B


Trispecific antibody 1
BGCB491
TS-F2-5
hIgG1 LALA isotype
Cell killing (%)
30
20
10
0
-4
-2
0
2
Log[antibody concentration]/nM

Fig. 8C


Trispecific antibody 1
BGCB491
TS-F2-5
hIgG1 LALA isotype
Cell killing (%)
50
40
30
20
10
0
-4
-2
0
2
Log[antibody concentration]/nM

Fig. 8D


Trispecific antibody 1
BGCB491
TS-F2-5
hIgG1 LALA isotype
Cell killing (%)
20
10
0
-10
-10
-8
-6
-4
-2
0
2
Log[antibody concentration]/nM

Fig. 8E


Trispecific antibody 1
BGCB491
TS-F2-5
Teclistamab analogue (BCMA/CD3)
hIgG1 LALA isotype
Cell killing (%)
60
40
20
0
-10
-8
-6
-4
-2
0
2
Log[antibody concentration]/nM

Fig. 9



Fig. 10A



Fig. 10B


Tumor volume (mm³)
3000
2500
2000
1500
1000
500
0
0
5
10
15
Days
hIgG1 LALA isotype, 4ug/kg
Teclistamab (BCMA/CD3), 4ug/kg
Trispecific antibody 1, 4ug/kg
Trispecific antibody 2, 5ug/kg
Teclistamab, 4ug/kg + Talquetamab, 4ug/kg

Fig. 11


Tumor volume (mm³)
5000
4000
3000
2000
1000
0
0
3
6
9
12
15
18
Days
hIgG1 LALA isotype, 30ug/kg
Trispecific antibody 1, 1ug/kg
Trispecific antibody 1, 6ug/kg
Trispecific antibody 1, 30ug/kg
BGCB491, 6ug/kg
TS-F2-5, 7ug/kg

Fig. 12



Fig. 13



Fig. 14A



Fig. 14B



Fig. 15A



Fig. 15B



Fig. 16



Fig. 17A



Fig. 17B



Fig. 18A



Fig. 18B



Fig. 19A



Fig. 19B